Packaging & Labelling

Packaging & Labelling
Product Description

Primary and Secondary packaging and labelling capabilities 

Eramol

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2026
  • Certificates:
    4
  • Employees:
    25 - 49
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
Specifications
  • Details
    Primary and Secondary packaging and labelling capabilities 

Eramol

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2026
  • Certificates:
    4
  • Employees:
    25 - 49
Company types
CMO/CDMO
Primary activities
Contract Manufacturer

More Products from Eramol (4)

  • Non Sterile Manufacturing

    Product Non Sterile Manufacturing

    Oral dosage forms (tablets, capsules, oral liquids)Actives and placebos
  • QP Release

    Product QP Release

    QP Release into UK & EU market
  • Sterile Fill Finish

    Product Sterile Fill Finish

    Aseptic and Terminal sterilisationsmall moleculelarge molecule/biologicsADCsATMPSCell & Gene TherapyPeptidesOligonucleotidesRadiopharmaViral Vectors
  • Storage & Distribution

    Product Storage & Distribution

    Storage and global distribution capabilities 

Eramol resources (1)

  • News New Sterile Manufacturing Facility (End to End CMO service)

    Eramol’s new sterile manufacturing facility at its Sevenoaks campus is a purpose-built, EU GMP Annex 1 aligned site designed to support early-phase sterile injectable programmes. The facility features isolator-based aseptic fill-finish and terminal sterilisation, with phase-appropriate batch sizes and a strong focus on sterility assurance and product protection, achieving <1% line losses. Fully integrated with Eramol’s wider services, the facility provides an end-to-end sterile solution including packaging and labelling, QC testing, UK/EU QP release, regulatory support, GMP/GDP storage and global distribution, with planned expansion to support later-stage and commercial manufacturing.